{"analyses":[{"ciLowerLimit":"15.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"54.62","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0005","paramType":"Difference in Response Rates","paramValue":"37.50","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.80","upperLimit":"77.27","value":"62.5"},{"groupId":"OG001","lowerLimit":"12.69","upperLimit":"41.20","value":"25.0"},{"groupId":"OG002","lowerLimit":"21.82","upperLimit":"65.98","value":"42.9"},{"groupId":"OG003","lowerLimit":"47.57","upperLimit":"67.09","value":"57.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"106"}],"units":"Participants"}],"description":"BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \\& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\\>mediastinum but ≤liver;4=UT moderately\\>liver;5=UT markedly higher than liver \\&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \\& ELS, score=4 or 5, reduced UT than baseline (BL) \\& residual mass of any size;residual UT\\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \\& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \\& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm C (Phase II Randomization): Pola+BR in DLBCL"},{"description":"Participants with DLBCL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG001","title":"Arm D (Phase II Randomization): BR in DLBCL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG002","title":"Arm F (Phase II Expansion): Pola+BG in DLBCL"},{"description":"Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG003","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.","reportingStatus":"POSTED","timeFrame":"Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)","title":"DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}